SR 2025 VIDEO

I am pleased to announce the publication of our 2025 sustainability report. This report highlights our Sustainability Approach and , and our commitment to Acting Responsibly. For 50 years we've focused on producing high-quality medicines and contributing to a healthy society. Our aim is to put better health within reach every day. 

Our approach to sustainability rests on four key pillars, at the center, our core pillar of advancing health and wellbeing, and in support are our three pillars on empowering our people, protecting the environment, and operating transparently and ethically. 

In 2025, we created a clear  and coherent access to medicine strategy and introduced a set of metrics through which we can measure and benchmark our performance. 

Globally, we were able to treat more than 222 million patients, which demonstrates the true impact of our efforts. 2025 also saw continued work with our communities by providing educational opportunities, food donations and offering medicines to those most in need. And in total we donated medicines worth more than $2.6m. Community engagement and social responsibility is something that is ingrained in our culture, over the course of the year we reached more than 560,000 people through our community outreach programmes. 

We also continued to support out people. Our recently completed People Voice Survey showed employee engagement at 73% and employee enablement at 68%. The results will help guide our employee programmes and help continue to make Hikma a great place to work. 

Throughout 2025, we continued to improve  our environmental performance, focusing specifically on mitigating our emissions and establishing a more robust approach to water management, particularly in the water scarce countries where we operate. As an example, we established water stewardship and absolute CO2 emission reduction KPIs that link directly to Executive remuneration.

We also opened a new 1MW solar park in Jordan, and have plans to go much further in the coming years.

Finally, we also spent 2025 continuing to focus on ethics and transparency across our value chain, and taking serious measures to safeguard fundamental human rights both in the upstream and downstream parts of our business. 

This year, for the first time we asked our key suppliers to rate us on how well we work with them, and how we uphold our own Code of Conduct.

We believe that our high-quality medicines should reach everyone who needs them . This is why we focus on acting responsibly, that means advancing health and wellbeing, empowering our people, protecting the environment, and operating transparently and ethically.